hTERT-based therapy: A universal anticancer approach (Review)

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 1945-1952

  Lü, Mu Han ^a   Liao, Zhong Li ^a   Zhao, Xiao Yan ^a   Fan, Ya Han ^a   Lin, Xian Long ^a   Fang, Dian Chun ^a   Guo, Hong ^a   Yang, Shi Ming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Human telomerase reverse transcriptase; Telomerase; Therapy

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CANCER VACCINE; I 540; ISOLEUCYLLEUCYLALANYLLYSYLPHENYLALANYLLEUCYLHISTIDINYLTRYPTOPHYLLEUCINE; K 973; LYSYLLEUCYLPHENYLALANYLGLYCYLVALYLLEUCYLARGINYLLEUCYLLYSINE; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; TETRACYCLINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; BIOGENESIS; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CD4+ T LYMPHOCYTE; CONFERENCE PAPER; DENDRITIC CELL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SUICIDE GENE THERAPY; T LYMPHOCYTE; TUMOR IMMUNITY;

APOPTOSIS; CELL PROLIFERATION; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TELOMERASE;

EID: 84868094033     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2036     Document Type: Conference Paper

References (51)

1. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ and Reddel RR: Protein composition of catalytically active human telomerase from immortal cells. Science 315:1850-1853, 2007. (Pubitemid 46580145)
2. Campisi J, Kim SH, Lim CS and Rubio M: Cellular senescence, cancer and aging: the telomere connection. Exp Gerontol 36:1619-1637, 2001. (Pubitemid 32982869)
3. Zvereva MI, Shcherbakova DM and Dontsova OA: Telomerase: structure, functions, and activity regulation. Biochemistry 75:1563-1583, 2010.
4. Raptis S and Bapat B: Genetic instability in human tumors. EXS 303-320, 2006.
5. Lü MH, Deng JQ, Cao YL, Fang DC, Zhang Y and Yang SM: Prognostic role of telomerase activity in gastric adenocarcinoma: a meta-analysis. Exp Ther Med 3:728-734, 2012.
6. Harley CB: Telomerase and cancer therapeutics. Nat Rev Cancer 8:167-179, 2008. (Pubitemid 351305939)
7. Onoda N, Ogisawa K, Ishikawa T, Takenaka C, Tahara H, Inaba M, Takashima T and Hirakawa K: Telomerase activation and expression of its catalytic subunits in benign and malignant tumors of the parathyroid. Surg Today 34:389-393, 2004. (Pubitemid 38626483)
8. Sorbe B, Bohr L, Karlsson L and Bermark B: Combined external and intracavitary irradiation in treatment of advanced cervical carcinomas: predictive factors for local tumor control and early recurrences. Int J Oncol 36:371-378, 2010.
9. Shay JW and Wright WE: Implications of mapping the human telomerase gene (hTERT) as the most distal gene on chromosome 5p. Neoplasia 2:195-196, 2000. (Pubitemid 30346074)
10. Yu ST, Chen L, Wang HJ, Tang XD, Fang DC and Yang SM: hTERT promotes the invasion of telomerase-negative tumor cells in vitro. Int J Oncol 35:329-336, 2009.
11. Park JI, Venteicher AS, Hong JY, Choi J, Jun. S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, et al: Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460:66-72, 2009.
12. KIP1. Int J Oncol 23:1703-1708, 2003.
13. Papanikolaou V, Iliopoulos D, Dimou I, Dubos S, Tsougos I, Theodorou K, Kitsiou-Tzeli S and Tsezou A: The involvement of HER2 and p53 status in the regulation of telomerase in irradiated breast cancer cells. Int J Oncol 35:1141-1149, 2009.
14. Meeran SM, Patel SN, Chan TH and Tollefsbol TO: A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev Res 4:1243-1254, 2011.
15. Zhang YF, Tang XD, Gao JH, Fang DC and Yang SM: Heparanase: a universal immunotherapeutic target in human cancers. Drug Discov Today 16:412-417, 2011.
16. Amarnath SM, Dyer CE, Ramesh A, Iwuagwu O, Drew PJ and Greenman J: In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer. Int J Oncol 25:211-217, 2004.
17. Titu LV, Loveday RL, Madden LA, Cawkwell L, Monson JR and Greenman J: Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients. Oncol Rep 12:871-876, 2004.
18. Naito K, Ueda Y, Itoh T, Fuji N, Shimizu K, Yano Y, Yamamoto Y, Imura K, Kohara J, Iwamoto A, et al: Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity. Int J Oncol 28:1481-1489, 2006.
19. Chen L, Liang GP, Tang XD, Chen T, Cai YG, Fang DC, Yu ST, Luo YH and Yang SM: In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus. Biochem Biophys Res Commun 351:927-934, 2006. (Pubitemid 44715875)
20. Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, Turaga V, Higgins J, Boczkowski D, Gilboa E and Dannull J: Enhanced induction of telomerase-specific CD4 (+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 62:5041-5048, 2002. (Pubitemid 34984432)
21. + regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol 242:39-46, 2012.
22. Liu J P, Chen W, Schwarer AP and Li H: Telomerase in cancer immunotherapy. Biochim Biophys Acta 1805:35-42, 2010.
23. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P and Zanetti M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97:4796-4801, 2000. (Pubitemid 30238637)
24. Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P and Zanetti M: Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 99:12275-12280, 2002.
25. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, et al: HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900-5906, 2002. (Pubitemid 34556179)
26. *0201 restricted, naturally processed CTL epitope. Cancer Immunol Immunother 56:1755-1763, 2007. (Pubitemid 47313080)
27. + T lymphocytes. Blood 106:2663-2670, 2005. (Pubitemid 41510738)
28. Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, Kuzushima K, Takiguchi M and Kaneko S: Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 43:1284-1294, 2006. (Pubitemid 43980107)
29. *0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res 12:3158-3167, 2006. (Pubitemid 43837365)
30. Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, Langlade-Demoyen P and Zanetti M: Immunogenic HLA-B7-restricted peptides of hTRT. Int Immunol 18:1707-1718, 2006. (Pubitemid 44884033)
31. Bernardeau K, Kerzhero J, Fortun A, Moreau-Aubry A, Favry E, Echasserieau K, Tartour E, Maillere B and Lang F: A simple competitive assay to determine peptide affinity for HLA class II molecules: a useful tool for epitope prediction. J Immunol Methods 371:97-105, 2011.
32. Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G and Gaudernack G: hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 60:809-818, 2011.
33. Wang J, Yu L, Li J, Deng R and Wang X: Characterization of a human telomerase reverse transcriptase sequence containing two antigenic epitopes with high affinity for human leucocyte antigen. Biotechnol Appl Biochem 48:93-99, 2007. (Pubitemid 47572186)
34. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL and Nadler LM: Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 7:3343-3348, 2001. (Pubitemid 33069964)
35. Schroers R, Huang XF, Hammer J, Zhang J and Chen SY: Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 62:2600-2605, 2002. (Pubitemid 34462740)
36. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF and Chen SY: Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9:4743-4755, 2003. (Pubitemid 37323277)
37. Tang XD, Wang GZ, Guo J, Lu MH, Li C, Li N, Chao YL, Li CZ, Wu YY, Hu CJ, Fang DC and Yang SM: Multiple antigenic peptides based on H-2Kb-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo. Mol Cancer Ther 11:1183-1192, 2012.
38. Parker KC, Bednarek MA and Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175, 1994.
39. Niu BL, Du HM, Shen H P, Lian ZR, Li JZ, Lai X, Wei SD, Zou LQ and Gong JP: Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine. Vaccine 30:3395-3404, 2012.
40. Murofushi Y, Nagano S, Kamizono J, Takahashi T, Fujiwara H, Komiya S, Matsuishi T and Kosai K: Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerasedependent targeted cancer gene therapy. Int J Oncol 29:681-688, 2006.
41. Jacob D, Davis J, Zhu H, Zhang L, Teraishi F, Wu S, Marini FC III and Fang B: Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 10:3535-3541, 2004. (Pubitemid 38685464)
42. Kyo S and Inoue M: Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy? Oncogene 21:688-697, 2002. (Pubitemid 34146272)
43. Iliopoulos D, Satra M, Drakaki A, Poultsides GA and Tsezou A: Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. Int J Oncol 34:391-399, 2009.
44. Gu J, Zhang L, Huang X, Lin T, Yin M, Xu K, Ji L, Roth JA and Fang B: A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 21:4757-4764, 2002. (Pubitemid 34879451)
45. Zhao P, Wang C, Fu Z, You Y, Cheng Y, Lu X, Lu A, Liu N, Pu P, Kang C, Salford LG and Fan X: Lentiviral vector mediated siRNA knock-down of hTERT results in diminished capacity in invasiveness and in vivo growth of human glioma cells in a telomere length-independent manner. Int J Oncol 31:361-368, 2007.
46. Liu X, Huang H, Wang J, Wang C, Wang M, Zhang B and Pan C: Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol 82:17-23, 2011.
47. Gandellini P, Folini M, Bandiera R, De Cesare M, Binda M, Veronese S, Daidone MG, Zunino F and Zaffaroni N: Downregulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol 73:1703-1714, 2007. (Pubitemid 46601404)
48. Kota SK and Balasubramanian S: Cancer therapy via modulation of micro RNA levels: a promising future. Drug Discov Today 15:733-740, 2010.
49. Hao ZM, Luo JY, Cheng J, Li L, He D, Wang QY and Yang GX: Intensive inhibition of hTERT expression by a ribozyme induces rapid apoptosis of cancer cells through a telomere length-independent pathway. Cancer Biol Ther 4:1098-1103, 2005. (Pubitemid 41598564)
50. Sachsinger J, Gonzalez-Suarez E, Samper E, Heicappell R, Muller M and Blasco MA: Telomerase inhibition in RenCa, a murine tumor cell line with short telomeres, by overexpression of a dominant negative mTERT mutant, reveals fundamental differences in telomerase regulation between human and murine cells. Cancer Res 61:5580-5586, 2001. (Pubitemid 32694946)
51. Cesare AJ and Reddel RR: Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 11:319-330, 2010.